56.45
0.05%
-0.03
After Hours:
56.45
Catalent Inc. stock is currently priced at $56.45, with a 24-hour trading volume of 1.84M.
It has seen a -0.05% decreased in the last 24 hours and a -2.57% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $56.38 pivot point. If it approaches the $56.61 resistance level, significant changes may occur.
Catalent Inc. Stock (CTLT) Financials Data
Catalent Inc. (CTLT) Revenue 2023
CTLT reported a revenue (TTM) of $4.10 billion for the quarter ending December 31, 2023, a -13.38% decline year-over-year.
Catalent Inc. (CTLT) Net Income 2023
CTLT net income (TTM) was -$1.30 billion for the quarter ending December 31, 2023, a -433.85% decrease year-over-year.
Catalent Inc. (CTLT) Cash Flow 2023
CTLT recorded a free cash flow (TTM) of -$263.00 million for the quarter ending December 31, 2023, a +29.11% increase year-over-year.
Catalent Inc. (CTLT) Earnings per Share 2023
CTLT earnings per share (TTM) was -$7.06 for the quarter ending December 31, 2023, a -412.39% decline year-over-year.
Catalent Inc. Stock (CTLT) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Gunther Scott | SVP, Quality & Reg. Affairs |
Mar 15 '24 |
Sale |
56.20 |
387 |
21,749 |
29,506 |
Ryan Michelle R | Director |
Aug 31 '23 |
Buy |
49.98 |
1,000 |
49,980 |
1,979 |
GREISCH JOHN J | Executive Chair |
Aug 30 '23 |
Buy |
50.24 |
21,000 |
1,055,040 |
34,000 |
Maselli Alessandro | President & CEO |
Aug 24 '23 |
Sale |
44.54 |
2,071 |
92,245 |
88,004 |
Fasman Steven L | EVP & Chief Admin Officer |
Aug 24 '23 |
Sale |
44.65 |
817 |
36,479 |
73,789 |
Gennadios Aristippos | Group Pres. Pharma & Consumer |
Aug 24 '23 |
Sale |
44.49 |
396 |
17,618 |
96,552 |
Grippo Michael J | SVP, Strategy & Corp. Dev. |
Aug 24 '23 |
Sale |
44.50 |
390 |
17,355 |
24,449 |
Pravda Ricardo | Chief Transformation Officer |
Aug 24 '23 |
Sale |
44.47 |
379 |
16,854 |
30,224 |
Hopson Ricky | Pres. Clinical Dev Supply Div |
Aug 24 '23 |
Sale |
44.56 |
276 |
12,299 |
22,040 |
Gunther Scott | SVP, Quality & Reg. Affairs |
Aug 24 '23 |
Sale |
44.57 |
269 |
11,989 |
29,932 |
Catalent Inc. Stock (CTLT) Latest News
Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?
The Motley Fool
Did Novo Nordisk Just Get a Jump on Eli Lilly?
The Motley Fool
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
Zacks Investment Research
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
Zacks Investment Research
Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why
The Motley Fool
Record-High S&P 500 Propels SPY ETF To $500-Billion Milestone, Nvidia Tops $2 Trillion, Broadcom Surpasses Tesla
Benzinga
About Catalent Inc.
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics and Specialty Drug Delivery segment formulates, develops, and manufactures small molecule and biologic drug products in prefilled syringes, vials and cartridges, blow-fill-seal unit doses, and injectable formats; develops biologic cell lines; manufactures biologic drug substances; and offers bioanalytical development and testing services. The Oral Drug Delivery segment formulates, develops, and manufactures oral dosage forms using proprietary and conventional drug delivery technologies, such as Zydis, OptiDose CR, OptiPact, OptiForm API and Solution Suite, Pharmatek SD Spray Drying, OptiMelt hot melt extrusion, Micron particle size reduction, and FlexDose; and provides stick pack formulation and filling, and analytical development and testing services. The Clinical Supply Services segment offers Manufacturing, packaging, labeling, storage, distribution, and inventory management for drugs and biologics clinical trials; FastChain demand-led clinical supply services; clinical e-solutions and informatics; and comparator sourcing services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.
Cap:
|
Volume (24h):